American Journal of Kidney Diseases
Volume 43, Issue 5 , Pages 772-781, May 2004

Strategies for preservation of ovarian and testicular function after immunosuppression

  • Shona Pendse, MD

      Affiliations

    • Renal Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
    • ,
  • Elizabeth Ginsburg, MD

      Affiliations

    • Renal Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
    • ,
  • Ajay K Singh, MD

      Affiliations

    • Renal Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
    • Corresponding Author InformationAddress reprint requests to Ajay K. Singh, MD, Clinical Director, Renal Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 USA

Received 20 October 2003; received in revised form 26 January 2004; accepted 26 January 2004.

Abstract 

Gonadal toxicity as a side effect of cyclophosphamide therapy is a common long-term problem in the treatment of a variety of glomerular diseases. In both men and women treated with cyclophosphamide, the consequences of infertility can have great physical and emotional consequences; thus, this issue often has a critical role in the decision to decline treatment with cyclophosphamide. There exists a critical need for strategies for preservation of fertility in both men and women who require treatment with cyclophosphamide. This review explores emerging therapeutic options in this arena, which include sperm and oocyte cryopreservation, medical treatments such as testosterone therapy for men and gonadotropin-releasing hormone agonist therapy for both men and women, and, finally, the relatively new strategy of germ-cell transplantation for both ovarian and testicular tissue, which still remains in the experimental stages.

Keywords:  Immunosuppression, cytotoxic agents, glomerulonephritis, infertility, ovarian function, testicular function

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0272-6386(04)00129-5

doi:10.1053/j.ajkd.2004.01.008

American Journal of Kidney Diseases
Volume 43, Issue 5 , Pages 772-781, May 2004

Article Tools